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Purpose: To report the findings of the clinical and molecular evaluation in a Greek family with fleck corneal dystrophy
(CFD).
Methods: A 58-year-old woman was seen on routine ophthalmic examination and diagnosed as having CFD. All available
family members were examined to evaluate the clinical findings and inheritance of the disease. Twenty members of the
family in five generations underwent slit-lamp examination. Eleven were females and nine males, aged from two years
to 85 years old. Blood samples were available from four patients with CFD and seven unaffected relatives, and the DNAs
were subjected to molecular screening of the phosphoinositide kinase, five finger-containing (PIKFYVE) gene by direct
sequencing or denaturing high performance liquid chromatography (DHPLC).
Results: The clinical evaluation revealed six family members (five females and one male) with CFD. In two CFD patients
early cataract formation was noticed. All patients affected with the corneal dystrophy were asymptomatic. The molecular
analyses demonstrated the existence of a novel c.3060–3063delCCTT (p.P968Vfs23) mutation in PIKFYVE in all CFD
patients tested but in none of the six unaffected family members. No molecular screening was performed in the seventh
unaffected member as the causative mutation was clearly transmitted from his affected wife to his affected son.
Conclusions: We report on the clinical and molecular findings of a five generation Greek family with CFD and we
conclude that the novel c.3060–3063delCCTT (p.P968Vfs23) mutation in PIKFYVE, which segregated with the disease,
was the causative mutation in this family.
Fleck corneal dystrophy (CFD, OMIM 121850) is a rare
autosomal dominant stromal dystrophy beginning early in life
and is characterized by flat, gray-white, tiny flecks scattered
throughout the stroma. The flecks have comma, oval, circular
or stellate shapes. Histologically only abnormal keratocytes
are involved, which contain excess glycosaminoglycan and
complex lipids. Typically, the stroma in between the flecks is
clear, and the endothelium, epithelium, Bowman layer, and
Descemet membrane are normal. The flecks in CFD may
appear as early as at two years of age or even at birth, and
generally they are reported not to progress significantly
throughout life. Although CFD is thought to be rare, specific
incidence figures are difficult to obtain. François and Neetens
described the condition for the first time in 1957 [1]. Several
reports have proven the autosomal dominant pattern of
inheritance of this corneal dystrophy [2-4]. CFD has been
linked to chromosome 2q35 [5] due to mutations in the
phosphoinositide kinase, five finger-containing (PIKFYVE)
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gene, also known as PIP5K3 (phosphatidylinositol-3-
phosphate/phosphatidylinositol 5-kinase type III) [4].
PIKFYVE belongs to a large family of lipid kinases that alter
the phosphorylation status of intracellular
phosphatidylinositol [6]. The content of phosphatidylinositol
3,5-bisphosphate (PtdIns(3,5)P2) in endosomal membranes
changes dynamically with fission and fusion events that
generate or absorb intracellular transport vesicles. PIKFYVE
is the PtdIns(3,5)P2-producing component of a trimolecular
complex that tightly regulates the level of PtdIns(3,5)P2.
Other components of this complex are the PIKFYVE activator
VAC14 and the PtdIns(3,5)P2 phosphatase FIG4 [7]. In
addition to its phosphoinositide 5-kinase activity, PIKFYVE
also has protein kinase activity [8]. PIKFYVE contains 41
coding exons spanning more than 89 kb, and encodes a 2,089-
amino acid protein [4].
In this study we present on the clinical and molecular
genetic examinations performed on CFD patients and
unaffected relatives in a five generation family of Greek
origin.
METHODS
Family participants: A 58-year-old woman (Figure 1, II:6)
was seen on routine ophthalmic examination and diagnosed
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as having CFD. All available family members were examined
to evaluate clinical findings and the genetic inheritance
pattern of the disease. Twenty members of the family in five
generations (Figure 1, Ι:1, II:1, II:2, ΙΙ:6, II:7, II:8, II:9, III:2,
III:9, III:10, III:11, III:12, III:13, III:14, III:16, IV:1, IV:7, IV:
9, IV:10, V:1) underwent slit-lamp examination. Eleven were
females (Figure 1, Ι:1, II:2, ΙΙ:6, II:8, III:2, III:10, III:11, III:
14, IV:1, IV:9, V:1) and nine males (Figure 1, II:1, II:7, II:9,
III:9, III:12, III:13, III:16, IV:7, IV:10), aged from two years
to 85 years old.
Sequencing and DHPLC analyses: Blood samples were
available from four patients with CFD (Figure 1, II:2, II:6, III:
11, and III:13) and seven unaffected relatives (Figure 1, II:1,
II:7, II:9, III:2, III:10, III:12, and III:14). DNA was isolated
from EDTA-anticoagulated blood samples by a standard
Figure 2. Photo of CFD in case II:6.
salting out procedure [9]. Coding exons and adjacent intronic
sequences of PIKFYVE were amplified from genomic DNA
of the proband (Figure 1, II:6) by use of the primers shown in
Appendix 1. PCR amplification of each of the 41 exons was
performed in 20 μl reactions involving 2.5 U of AmpliTaq
Gold (Applied Biosystems, Foster City, CA), 2 μl of 10×
AmpliTaq Gold Buffer, 1.9 mM MgCl2, 0.25 mM dNTPs,
0.25 mM of primers, and 40 mg of genomic DNA. PCR
cycling conditions consisted of an initial 10 min denaturation
step at 95 °C for 5 min; 32 cycles at 94 °C for 40 s, 55 °C for
30 s (61 °C for exon 19b), and 72 °C for 40 s; and a final
elongation step at 72 °C for 7 min. The PCR templates were
sequenced using ABI Dye Terminator (Applied Biosystems,
Foster City, CA), version 1, in a final reaction volume of
Figure 3. Cataract formation in case II:6.
Figure 1. Pedigree of the family with CFD.
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10 μl. Products of the sequencing reactions were purified
using the Performa DTR gel-filtration system (Edge
BioSystems, Gaithersburg, MD) and were run on a 3100 ABI
genetic analyzer (Applied Biosystems). Sequences were
aligned with the reference genomic sequence (GenBank
NM_015040) using the Seqman program of the DNASTAR
package (DNASTAR, Inc., Madison, WI) or Chromas,
version 2.23 (Technelysium Pty Ltd, Brisbane, Australia).
The primer sets and annealing temperatures used are shown
in Appendix 1. Denaturing high performance liquid
chromatography (DHPLC) was used to test co-segregation by
verifying the results of direct sequencing of the proband to the
other affected patients (Figure 1, II:2, III:11, and III:13). PCR
products were screened on a WAVE system (Transgenomics,
UK) at a temperature of 60.1 °C and starting at 58.5% B buffer.
Figure 4. Photo of CFD in case III:11.
Figure 5. Photo of CFD in case IV:9.
Written informed consent was obtained from all
participants. The clinical and molecular examinations were
in accordance with the Helsinki Declaration.
RESULTS
Slit-lamp examination revealed six members of the family
affected by CFD (Figure 1, I:1, II:2, II:6, III:11, III:13, and
IV:9). In two CFD patients early cataract formation was
noticed (Figure 1, II:2 66 years old, and II:6 58 years old). All
patients affected by the dystrophy were asymptomatic.
Inheritance of the condition in the family was compatible with
autosomal dominant inheritance. The clinical signs of patients
II:6, III:11, and IV:9 are presented in Figure 2 and Figure 3
(II:6), Figure 4 (III:11), and Figure 5 (IV:9).
Direct sequencing of the proband (II:6) revealed the
existence of a novel heterozygous c.3060–3063delCCTT
(p.P968Vfs23) mutation which is a 4-bp deletion in exon 20
of PIKFYVE (Figure 6). Co-segregation of the mutation tested
by DHPLC using the WAVE technology showed that the c.
3060–3063delCCTT (p.P968Vfs23) mutation was present in
all family members who were found to exhibit clinical signs
of CFD (Figure 1, II:2, III:11, III:13). WAVE results are
presented in Figure 7. Normal sequences were detected in
unaffected family members II:1, II:9, III:2, III:10, III:12, and
III:14 (Figure 1). No molecular screening was performed in
the seventh unaffected member (Figure 1, II:7) as the
causative mutation was clearly transmitted from his affected
wife (Figure 1, II:6) to his affected son (Figure 1, III:13).
However, an abnormal sequence was detected by WAVE in
the unaffected member II:9 (Figure 7), which subsequently
revealed the existence of the non-pathogenic heterozygous
rs2363468 (T>C) single nucleotide polymorphism (SNP) by
direct sequencing. The c.3060–3063delCCTT (p.P968Vfs23)
Figure 6. Partial sequence chromatograms of the PIKFYVE gene
presenting the c.3060–3063delCCTT mutation in heterozygosity
(upper panel), and a normal sequence (lower panel).
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mutation was not observed in 96 control individuals or in more
than 25 patients with CFD previously analyzed in our
laboratory.
DISCUSSION
Mutations in PIKFYVE have been implicated as the major
cause of CFD, an autosomal dominant human disease
characterized by the presence of numerous white flecks
scattered in all layers of the stroma [4]. PIKFYVE is a protein
important for post-Golgi vesicle processing. Mammalian
PIKFYVE is a member of an evolutionarily ancient gene
family of PtdIns(3,5)P2-synthesizing enzymes that are large
proteins, represented by a single-copy gene in most, if not all,
species with sequenced genomes, including the zebrafish
[10,11]. Most of the reported mutations are of nonsense and
frameshift type and occur in and around the Cpn60_TCP1
domain, predicting termination of the peptide before the
catalytic domain. Although the activity of the PIKFYVE
protein or the PtdIns(3,5P)2 levels have not been determined
under these conditions, it is expected that the mutations will
result in a loss of PIKFYVE function. Given the lethality of
the PIKfyve null mutations in model organisms [10], the
asymptomatic condition of the CFD patients is quite
surprising but could be attributed to the presence of one
normal allele. Histological findings in CFD indicating that the
corneal flecks are swollen keratocytes containing membrane-
limited empty vacuoles [12], are consistent with the
phenotypic changes seen under perturbed PIKfyve
functionality [10].
In this study we reported our findings on the clinical
evaluation and the molecular genetic examination of a family
presenting CFD. To our knowledge, this is the first reported
family of Greek origin. The pedigree (Figure 1) consisted of
a total of 40 individuals in five generations, among which 20
were subjected to clinical evaluation, whereas 20 were not.
Among the 20 examined, six were found to be affected by
CFD (Figure 1, I:1, II:2, II:6, III:11, III:13, and IV:9), and 14
were not affected (Figure 1, II:1, II:7, II:8, II:9, III:2, III:9, III:
10, III:12, III:14, III:16, IV:1, IV:7, IV:10, V:1). Early cataract
was noticed in two CFD patients (Figure 1, II:2 and II:6). Four
individuals are deceased, including one affected (Figure 1, I:
1) and three not examined persons (Figure 1, I:2, II:5, III:17).
Mutational screening of the PIKFYVE gene by direct
sequencing in the proband (Figure 1, II:6) revealed the
existence of the novel mutation c.3060–3063delCCTT in
heterozygosity (Figure 6). This 4-bp deletion was further
found to be the cause of a frameshift leading to the
p.P968Vfs23 alteration on the protein level. The mutation was
confirmed in all affected patients from which bloods were
drawn (Figure 1, II:2, III:11, III:13) by DHPLC analysis using
the WAVE technology. We conclude that the novel c.3060–
3063delCCTT (p.P968Vfs23) mutation in PIKFYVE, which
segregated with the disease, was the causative mutation in this
family.
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Appendix 1. PCR Primers for 41 exons of PIKFYVE (primers for DHPLC).
To access the data, click or select the words “Appendix
1.” This will initiate the download of a compressed (pdf)
archive that contains the file.
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